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Two issues that have become clinically relevant to the treatment of pneumonia over the past few years are the 
development of antibiotic resistance among respiratory pathogens and the increasing importance of the atypical 
respiratory pathogens-Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella spp. 
Resistance has become an important issue in Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus 
and Gram-negative rods. The ways by which bacteria become resistant to antibiotics include production of antibiotic- 
modifying enzymes, reduced access to target sites, efflux of antibiotic, change in the bacterial target site and the 
bypassing of inhibited pathways. In Streptococcus pneumoniae that are penicillin resistant, the mechanism is through 
alteration of the target site for penicillins (penicillin-binding proteins) and this may also confer resistance to some 
cephalosporins. Multidrug resistance has also been reported in some strains of pneurnococci. Of particular concern 
is resistance to macrolides mediated by the ermAM gene, which also confers resistance to lincosamides and 
streptogramin-6 drugs. In Staphylococcus aureus, resistance to virtually all P-lactam drugs is mediated by acquisition 
of the rnecA gene, which codes for the drug-resistant p-lactam target PBP2a. 
Antimicrobials are now needed that have enhanced activity against aerobic Gram-negative rods, atypical respiratory 
pathogens and Gram-positive cocci. 
Key words: Antibiotic resistance, atypical respiratory pathogens, Gram-negative rods, methicillin-resistant Staphylo- 
coccus aureus, respiratory tract infections, Streptococcus pneumoniae 
INTRODUCTION 
In order to consider the evolving needs in respiratory 
tract infections, both community- and hospital- 
acquired pneumonia need to be studied. The various 
pathogens that cause pneumonia depend upon the type 
of patient and also upon local epidemiologic factors. 
Unfortunately, despite the importance of pneumonia as 
a clinical entity, it is not a reportable disease and, 
therefore, the statistics are less than optimal. In the 
USA, there are approximately 3 x lo6 to 4 x lo6 cases 
of community-acquired pneumonia per year. The 
overall attack rate is 10-12 cases/1000 persons per year 
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[l-31. Attack rates are highest in the young, the old and 
in nursing home residents. Patients in the last group 
are also much more likely to require hospitalization. 
The overall rate of hospitalization for patients with 
pneumonia is 1/1000 cases, but for those who acquire 
the infection in a nursing home it is 33/1000 cases [4]. 
The overall mortality rate for those patients with 
community-acquired pneumonia requiring hospitaliza- 
tion is 21.9%, although age-specific mortality rates 
show that in certain subgroups it may exceed 50% [4]. 
Hospital-acquired or nosocomial pneumonia is 
defined as infection occurring 48 h or more after 
admission to hospital and is the second most common 
nosocomial infection. While crude mortality rates 
of up to 70% with pseudomonas and acinetobacter 
infection have been reported, the overall attributable 
mortality rate is in the range 33-50% [5]. 
In cases of community-acquired pneumonia, the 
primary concern is with Streptococcus pnenmoniae, and 
the atypical respiratory pathogens, such as Mycoplasmn 
pnenmoniae, Chlamydia pneumoniae, and Legionella spp. 
In certain cases, aerobic Gram-negative rods must also 
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be considered. In cases of nosocomial pneumonia, 
however, the main pathogens are aerobic Gram- 
negative rods and Staphylococcus aureus [6-91, 
An understanding of the pathogenesis of pneu- 
monia helps to explain these differences. For certain 
types of infection, such as with Aspeyillus spp., 
Legionella spp. and viruses, inhalation of an infected 
aerosol is likely to be the most significant route of 
infection. In pneumonia caused by aerobic Gram- 
negative rods, however, the most likely route of 
infection is by ‘silent’ or ‘micro’ aspiration of oro- 
pharyngeal secretions. Studies have shown that while 
oropharyngeal colonization by Gram-negative rods is 
unusual in healthy people, such colonization occurs 
with increasing frequency in those with underlying 
disease and in the elderly [10,11]. It has also been 
shown that in those with co-morbid Illness, cell surface 
fibronectin is lost from cells lining the oropharynx, 
thereby exposing receptors to Gram-negative rods 
[12,13]. The exposure of these receptors on the 
host cells allows Gram-negative rods a foothold that 
subsequently results in oropharyngeal colonization. 
Even healthy individuals in deep sleep can aspirate 
oropharyngeal contents, thereby allowing bacteria 
colonizing the oral area access to the lower respiratory 
tract [ 141. In individuals colonized by Gram-negative 
rods, silent aspiration delivers these virulent micro- 
organisms to the lower respiratory tract, where they 
eventually overwhelm local host defenses in the lung, 
resulting in the development of pneumonia. 
MICROBIOLOGICAL CONSIDERATIONS 
A detailed discussion of all the pathogens responsible 
for community- and hospital-acquired pneumonia is 
beyond the scope of this article. It  is important, 
however, to focus on the microbiological issues that 
have become relevant to the treatment of pneumonia 
over the past few years. The main clinically relevant 
issues are: 
1.  the development of resistance among both Gram- 
positive and Gram-negative pathogens 
2. the increasing awareness of the importance of 
infection by the atypical respiratory pathogens, 
such as Mycoplasma pneumoniae, C. pneumoniae and 
Lqionella spp. 
RESISTANCE ISSUES 
The development of resistance to antibiotics is 
associated with a number of adverse outcomes. In 
certain cases, more toxic and/or expensive antimicro- 
bials may have to be used. It has been estimated that 
the economic impact of antibiotic resistance in the 
USA is about $100 000 000 annually [15]. Patients who 
are infected with antibiotic-resistant pathogens are also 
more likely to have a longer stay (if hospitalized) and 
an elevated risk of dying [16]. 
Microbial resistance to antibiotics is not new 
and, since the discovery of penicilhn, it has been known 
that certain bacteria are able to produce an enzyme 
capable of hydrolyzing penicillin [ 171. Bacteria have 
presumably developed mechanisms of resistance in 
order to protect themselves against antimicrobial agents 
that they produce. It has been postulated that these 
resistance genes have escaped from soil microorganisms 
and, after passage and evolution in other bacteria, have 
entered those bacterial species that have direct contact 
with humans [18]. Strains showing resistance to tetra- 
cycline and streptomycin have been isolated from soil 
specimens and stool samples of inhabitants of the 
Solomon Islands, although these individuals have never 
been exposed to antibiotics [19]. In addition, amino- 
glycoside-modifying enzymes have been found in 
strains of Streptomyces that produce aminoglycoside 
antibiotics [20]. 
The main mechanisms that govern the emergence 
and spread of resistance of bacteria are mutation and the 
exchange of genetic information. The former refers to 
any change in the base sequence of DNA and may 
occur spontaneously or as a result of physical or 
chemical agents (e.g. ionizing radiation, ultraviolet light 
or heat). Genetic information necessary for resistance 
can be transferred via plasnllds or transposable genetic 
elements called transposons and insertion sequences. 
The processes by which the genetic information is 
exchanged or transferred from one cell to another are: 
transformation, transduction, conjugation and trans- 
position. 
There are a number of ways in which bacteria can 
become resistant to an antibiotic. For an antibiotic to 
achieve its antimicrobial effects, it must first gain access 
to and attach to a microbial target site. The micro- 
organism can block or prevent this occurring by 
employing a variety of strategies that are shown in 
Table 1 .  
Table 1 Mechanisms of bacterial resistance to antibiotics 
Production of antibiohc-modifying enzymes 
Keduced access to target sites 
Efflux of antibiotic 
Change in bacterial target site 
(a) target enzyme 
(b) cell wall precursor target 
(c)  ribosome target 
Bypassing inhibited pathways 
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A recent major problem has been the appearance 
of multiresistant organisms. This is thought to have 
occurred as a result of the acquisition by plasmids 
of resistance genes on different transposons that 
are acquired from the environment. Environmental 
conditions may help to enhance or select the new 
organisms. Selective pressure, particularly applied to 
antibiotics, is a very real phenomenon [21,22]. 
In certain microorganisms that are important 
etiologic agents of pneumonia, resistance has become 
an important issue. 
Streptococcus pneumoniae 
Streptococcus pneumoniae is the most common pathogen 
responsible for community-acquired pneumonia, and 
there are approximately 500 000 adult cases per year of 
pneumococcal pneumonia in the USA. Until relatively 
recently, resistance of pneumococci to penicillin was 
not an issue in North America. However, in 1994, data 
were published from a survey of 1500 isolates from 
30 centers showing that 24% of isolates were now 
relatively resistant to penicillin [23]. The guidelines 
of the National Committee for Clinical Labora- 
tory Standards (NCCLS) define strains with minimal 
inhibitory concentrations (MICs) to penicillin of 
< 0.06 mg/L as sensitive, 0.1-1 .O mg/L as inter- 
mediate, and 2 2 mg/L as resistant [24]. The first 
reported case of penicillin-resistant pneumococci 
was in a hypogammaglobulinemic Australian patient in 
1967 [25]. In 1972, pneumococcal resistance to 
penicillin was reported from New Guinea, and the first 
report from the USA followed in 1974, with isolation 
of the organism from the cerebrospinal fluid of a child 
in Chicago [26,27]. Similarly, in 1983 in Canada, a 
penicillin- and chloramphenicol-resistant pneumo- 
coccus was isolated from a child with meningitis [28]. 
Resistant isolates have now been found in almost every 
continent, with data available &om countries such as 
Malaysia, Brazil, South Africa, Hungary and Spain 
As mentioned above, bacteria may manifest 
resistance through a variety of mechanisms. For the 
penicillin-resistant pneumococcus, however, the only 
mechanism demonstrated to date that has been clini- 
cally significant is the alteration in the target site for 
penicillins (i.e. the penicillin-binding proteins (PBPs)). 
The PBPs are enzymes that are involved in bacterial 
cell wall synthesis and serve as the target sites of 
action of penicillin and other p-lactam agents. It is not 
surprising, therefore, that penicillin-resistant pneumo- 
cocci also tend to exhibit varying degrees of resistance 
to other penicillins and in some cases to certain 
cephalosporins as well. The situation, however, is 
complicated by the fact that strains have been found 
[29-341. 
that are resistant to third-generation cephalosporins, 
but which remain susceptible or moderately susceptible 
to penicillin [35,36]. 
An analysis of the nucleotide sequences of PBP 
genes shows that while the genes of susceptible 
strains of Streptococcus pneumoniae are uniform in their 
nucleotide sequence, those from resistant strains have 
a mosaic structure that is composed of regions some 
of which are similar to and some of which differ 
from their susceptible counterparts [37]. It has been 
postulated that the altered regions have been acquired 
from other bacterial species such as Streptococcus mitis by 
means of horizontal transfer of their genetic material 
Multidrug resistance refers to pathogens that are 
resistant to three or more antibiotics that have different 
mechanisms of antibacterial action. Multidrug-resistant 
Streptococcus pneumoniae was first reported in South 
Mica  in 1977, and such strains have now been isolated 
from a number of countries, including the USA 
[31,39]. One type of resistance that is of particular 
concern to clinicians is the resistance to macrolides 
mediated by the ermAM gene, which also confers 
resistance to lincosamides and streptogramin-B drugs 
~381. 
~401. 
Methicillin-resistant Staphy/ococcus aureus 
In a 1996 national nosocomial infection surveillance 
report, Staphylococcus aureus was the most common 
cause of nosocomial pneumonia, accounting for 19% 
of all isolates [41]. Most strains of Staphylococcus produce 
an extracellular penicillinase that hydrolyzes the p- 
lactam ring of penicillin and has necessitated the use 
of a penicillinase-resistant semi-synthetic penicillin, 
such as oxacillin, nafcillin, cloxacillin or methicillin. 
Methicillin-resistant Staphylococcus aureus can represent 
anywhere from 0% to over 40% of isolates of Staphylo- 
coccus nureus. However, the resistance to methicillin and 
to virtually all p-lactam drugs is mediated by the 
acquired chromosomal gene (mecA) which codes for 
the drug-resistant p-lactam target PBP2a [42]. 
Staphylococcus aureus typically colonizes the anterior 
nares of patients and from this site may spread to 
colonize or infect other sites [43]. Colonization by a 
methicillin-resistant strain is associated with a greater 
risk of infection than is colonization by a methicillin- 
sensitive strain. These organisms are usually susceptible 
to vancomycin, fusidic acid and, on occasion, to 
trimethoprim-sulfamethoxazole. 
Gram-negative rods 
This is a diverse group of bacteria that includes such 
pathogens as the Enterobacteriaceae (e.g. Escherichia 
coli, Klebsiella spp.) and the non-fermenters (e.g. 
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Pseudomonas aeruginosa and Acinetobacter spp.). Such 
pathogens have always been associated with nosocomial 
pneumonia, but as our understanding of the patho- 
genesis of pneumonia increases, their role as significant 
etiologic agents in community-acquired pneumonia 
has also been appreciated. This is particularly true 
in the elderly and in those with co-morbid illness. A 
number of studies have documented their importance 
in community-acquired pneumonia requiring hospital- 
ization, and incidence figures for these pathogens range 
from 5.9% to 25% [44-461. The importance of Gram- 
negative rods as pathogens was highlighted in a recent 
review, which indicated that in 14 studies reporting an 
association between infection caused by these bacteria 
and death, the median mortality was 33% [47]. 
The Enterobacteriaceae are Gram-negative facul- 
tative anaerobes comprising 102 species. Those species 
of clinical interest in pneumonia are Escherichia coli, 
Klebsiella spp., Enterobacter spp., Proteus spp. and Serratia 
marcescens. These organisms are found primarily in the 
intestines of humans and animals and are also referred 
to as coliforms. 
Haemophilus injuenzae has been recognized as a 
pathogen in acute exacerbations of chronic bronchitis 
and in community-acquired pneumonia in those with 
underlying lung disease. However, it is also being 
documented with increasing frequency as an important 
pathogen in nosocomial pneumonia, particularly in 
ventilated patients 148,491. It has been found in 
conjunction with another pathogen in about 50% of 
episodes and has been reported as occurring more 
frequently in association with Staphylococcus spp. [49]. It 
has been postulated that this may be a result either of 
the relatively high incidence of Staphylococcus as a 
pathogen in ventilator-associated pneumonia, or the 
fact that nicotinamide dinucleotide, which is necessary 
for the growth of H .  influenzae, is produced by 
staphylococci [49-5 11. 
The non-fermentative Gram-negative bacilli are 
aerobic, non-spore forming organisms and include 
Pseudomonas aeruginosa and Acinetobacter spp. Many of 
these bacteria are organisms that can survive in an 
aqueous environment, which is common, for example, 
in cystic fibrosis. 
As mentioned above, bacteria can become resistant 
to antibiotics by enzyme production. Pathogens are 
capable of producing a number of enzymes that can 
inactivate various types of antibiotics. These include 
the aminoglycosides, which can be modified by N- 
acetylation, O-nucleotidylation, and O-phosphory- 
lation, chloramphenicol, which is inactivated by 
chloramphenicol acetyltransferase, and (3-lactams, 
which may be rendered ineffective by (3-lactamase 
enzymes [52,53]. 
A number of different classification schemes for 
the P-lactamases exist based on substrate preference, 
susceptibility to inhibitors and means of genetic tran- 
scription. The last is the simplest scheme and is 
dependent solely upon whether enzyme production 
is mediated by a plasmid or by a chromosome. At 
present, there are more than 75 plasmid-mediated 
(3-lactamases that have been described for various 
Gram-negative bacteria and they may be classified 
as follows: broad-spectrum enzymes, oxacillinases, 
carbenicillinases, extended spectrum p-lactamases 
(ESBLs) and carbapenemases. 
The broad-spectrum plasmid-mediated enzymes 
were initially found only in the Enterobacteriaceae, but 
have now been reported in other bacteria, including 
H. influenzae, Moraxella catarrhalis (a Gram-negative 
coccus) and Pseudomonas aeruginosa. In a cross-Canada 
survey of H. iufluenzae, it was reported that 28.4% of 
isolates were p-lactamase producers [54]. 
From a clinical point of view, the most important 
of the plasmid-mediated enzymes are the ESBLs. These 
include oxyimino (3-lactamases that are Tem and Shv 
mutants and cephalosporinases that are unrelated to the 
Tem and Shv enzymes. Many of these are mutants of 
the broad-spectrum P-lactamases Tem-1 , Tem-2 and 
Shv-1 and, in many cases, differ from the parent 
enzyme by only one to three amino acids. This slight 
change, however, is sufficient to enhance the affinity of 
these enzymes for various broad-spectrum (3-lactam 
drugs. These mutants were first observed in Germany 
in 1983 and there are now over 24 variants that are 
commonly found in K. pneumoniae and less frequently 
in other Enterobacteriaceae [55-571. Production of 
ESBLs results in resistance of the pathogens to most of 
the broad-spectrum cephalosporins (e.g. cefiriaxone, 
cefotaxime and ceftazidime), as well as to the mono- 
bactam aztreonam [58,59]. The fluoroquinolone and 
carbapenem antibiotics, as well as the B-lactam/ 
p-lactamase inhibitors, such as piperacillin/tazobactam, 
are usually active against microorganisms producing 
ESBLs. 
The chromosomal P-lactamases are encoded by 
the ampC chromosomal gene and can be produced by 
almost all Gram-negative bacteria. P-Lactamase pro- 
duction may be either constitutive or inducible, and 
certain antibiotics, particularly first-generation cephalo- 
sporins, cephamycins and imipenem, may act as strong 
inducers of the enzyme. As a result of a spontaneous 
mutation in the bacterial genome, a stable derepressed 
mutant may appear that is capable of hyperproduction 
ofthe P-lactamase enzyme [60]. This has been reported 
when using third-generation cephalosporins for treat- 
ment of infections caused by Enterobacter spp. Use of 
such antibiotics has been associated with the emergence 
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of multiresistant Enterobacter isolates from blood cultures 
and with higher mortality rates [61]. Chromosomal 
genes that have been incorporated into plasmids have 
been reported in isolates of Escherichia coli and K. 
pneumoniae. These pathogens are capable of producing 
an ampC type of P-lactamase enzyme usually seen in 
Enterobacter cloacae. The genetic information, however, 
is transferred via a plasmid-mediated mechanism [62]. 
Antibiotics reach their target site in Gram-negative 
rods by first passing through the bacterial outer 
membrane via diffusion channels composed of porin 
proteins. Mutations may occur that delete certain porin 
proteins or modifj their characteristics and which may 
result in an organism that has lost a channel of entry for 
a specific antibiotic. Examples of this are the resistance 
of Pseudomonas aeruginosa and Enterobacter aerogenes to 
imipenem, mediated by the loss of an outer membrane 
protein, and the resistance of Pseudomonas aeruginosa and 
Serratia marcescens to fluoroquinolones [63-651. 
Changes in the target site itself may occur in one 
of three ways: a change in the target enzyme, cell wall 
precursor target, or the ribosome target. Changes in 
target enzymes such as the PBPs have been discussed in 
relation to Streptococcus pneumoniae and Staphylococcus 
aureus. Another target enzyme in which a change may 
result in bacterial resistance is DNA gyrase. Mutations 
in the ByrA or gyrB gene producing changes in DNA 
gyrase may cause resistance to the fluoroquinolones and 
have been described in the Enterobacteriaceae and 
Pseudomonas aeruginosa [66-681. 
ATYPICAL RESPIRATORY PATHOGENS 
legionnaire's disease 
Legionella spp. are fastidious aerobic Gram-negative 
rods. Their natural habitat is water, and of the 34 
species, L. pneumophila, serogroup 1, is the organism 
most commonly associated with pneumonia [69]. 
Although the mode of transmission is somewhat 
controversial, evidence currently exists for both 
inhalation of aerosols and aspiration [70,71]. 
The reported incidence of legionella infection 
varies substantially from study to study, with figures of 
1-16% being reported for both community-acquired 
and nosocomial infection [72,73]. Smokers, those 
with underlying lung disease, the elderly or patients 
receiving immunosuppressive agents, such as high-dose 
steroids, cyclosporin or azathioprine, have an elevated 
risk of infection [69]. 
The overall mortality rate for L. pneumophila 
pneumonia is 19% but this can vary from a low of 5% 
in those who are non-immunosuppressed and who 
have received appropriate therapy, to 80% in immuno- 
compromised patients who have not received appro- 
priate therapy [74]. 
Mycoplasma pneumoniae 
Of the atypical respiratory pathogens, Mycoplasma 
pneumoniae was the first to be associated with 
pneumonia. It is the smallest ftee-living organism and 
is considered to be intermediate between bacteria and 
viruses. Although infections are not thought to be 
seasonal, there does appear to be a 4-year cycle of 
epidemic activity, particularly in the UK [75]. 
Infection with this organism may result in a wide 
variety of clinical manifestations, including signs and 
symptoms of respiratory tract infection and extra- 
pulmonary manifestations, such as hemolytic anemia, 
neuropathy, myelitis and hepatitis. The incidence of 
pneumonia caused by Mycoplasma varies considerably, 
depending upon whether or not there was an epidemic 
at the time and whether appropriate diagnostic tests 
have been performed. Another important determinant 
of incidence is whether one is dealing with sporadic 
cases or whether there is an outbreak in an enclosed 
population (e.g. a dormitory or prison). Incidence rates 
of 4-51% have been reported, and in those aged over 
40 years, 11-17% [76,77]. 
CMamydia pneumoniae ( W A R )  
C. pneumoniae is an obligate intracellular parasite and a 
distinct species within the genus Chlamydia. It has been 
implicated in sporadic and epidemic cases of com- 
munity-acquired pneumonia worldwide, and incidence 
rates varying from 6 to 15% have been reported [78,79]. 
As with Mycoplasma pneumoniae infection, the clinical 
spectrum of infection with C. pneumoniae ranges from 
asymptomatic infection to life-threatening pneumonia. 
A report of a recent outbreak in three nursing homes 
in Ontario, Canada reported high attack rates ranging 
from 44% to 68%, as well as high mortality rates [80]. 
C. pneumoniae infection may occur in association with 
other pathogens, particularly Streptococcus pneumoniae. 
Many of the antibiotics used in clinical practice are 
ineffective against the atypical respiratory pathogens. 
This includes the p-lactams (penicillins, cephalosporins, 
carbapenems, monobactams), the aminoglycosides, the 
sulfonamides, lincosarnides, and glycopeptides. Treat- 
ment is usually in the form of a macrolide, a fluoro- 
quinolone, or doxycycline. 
MANAGEMENT ISSUES 
If one considers the various types of pathogens, the 
types of patients who may become infected and the 
long list of available antibiotics, there are endless 
numbers of permutations and combinations possible. 
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The pathogens may be any one of or combinations of 
Gram-positive cocci, Gram-negative rods or atypical 
pathogens. Patients may have no risk factors or multiple 
risk factors for infection, and the infection itself may be 
mild, moderate or severe. The decision as to which 
antibiotic regimen to use is made more difficult by the 
fact that in over 50% of cases, the etiologic agent may 
not be known. There are data in severe community- 
acquired pneumonia that suggest that even if the 
pathogen is known, this knowledge might not change 
the outcome [45,46,81]. It  has been shown that in cases 
of severe community-acquired pneumonia, inappro- 
priate initial therapy was an independent predictor for 
mortality [82]. This emphasizes the need for aggressive 
initial treatment of pneumonia, particularly in those 
with severe infection. 
Given that the problem of resistant bacteria, the 
possibility of infection with more than one pathogen, 
the increasing importance of the atypicals and the 
substantial mortality associated with severe com- 
munity-acquired pneumonia in certain patient groups 
and with hospital-acquired pneumonia must be con- 
sidered, the use of agents that provide adequate cover 
against the likely pathogens is very important. It  is now 
clear that antimicrobials with activity against the aerobic 
Gram-negative rods, atypical respiratory pathogens and 
the Gram-positive cocci, such as Staphylococcus aureus 
and Streptococcus pneumoniae, are needed. 
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